Overview

Hepatic Arterial Infusion (HAI) of Abraxane

Status:
Completed

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is find the highest tolerated dose of Abraxane (nab-paclitaxel) that can be given directly into the liver of patients with advanced cancer that has spread to the liver.

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

National Comprehensive Cancer Network

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel